Subodh Verma




Please note: Dr. Verma will not take students in summer.

Dr. Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr. Verma was recently awarded the 2021 Lister Prize in Surgery from the University of Toronto in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in April 2021, Dr. Verma has an h-index of 100 and his work has been cited over 50,000 times.

Dr. Verma has published extensively in highly impactful journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI. He is an Associate Editor of the European Heart Journal. Dr. Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr. Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr. Verma had/has leadership roles on 10 contemporary global heart failure trials – several of which have let to paradigm changes in how individuals all around the world who live with diabetes and heart failure are now managed. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies.

Dr. Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.


Recent Publications

  1. Odutayo, A, da Costa, BR, Pereira, TV, Garg, V, Iskander, S, Roble, F et al.. Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression. J Am Heart Assoc. 2021; :e019918. doi: 10.1161/JAHA.120.019918. PubMed PMID:34514812 .
  2. Ladha, KS, Mistry, N, Wijeysundera, DN, Clarke, H, Verma, S, Hare, GMT et al.. Recent cannabis use and myocardial infarction in young adults: a cross-sectional study. CMAJ. 2021;193 (35):E1377-E1384. doi: 10.1503/cmaj.202392. PubMed PMID:34493564 PubMed Central PMC8443297.
  3. Hibino, M, Dhingra, NK, Verma, S. Increased patency with comparable mortality and revascularization risk: Is the case for no-touch vein harvesting open and shut?. J Card Surg. 2021; :. doi: 10.1111/jocs.15973. PubMed PMID:34477262 .
  4. Vaduganathan, M, Inzucchi, SE, Sattar, N, Fitchett, DH, Ofstad, AP, Brueckmann, M et al.. Effects of Empagliflozin on Insulin Initiation or Intensification in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from the EMPA-REG OUTCOME® Trial. Diabetes Obes Metab. 2021; :. doi: 10.1111/dom.14535. PubMed PMID:34463409 .
  5. Kosmopoulos, A, Bhatt, DL, Meglis, G, Verma, R, Pan, Y, Quan, A et al.. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. iScience. 2021;24 (9):103040. doi: 10.1016/j.isci.2021.103040. PubMed PMID:34462732 PubMed Central PMC8388138.
  6. Pandey, AK, Okaj, I, Kaur, H, Belley-Cote, EP, Wang, J, Oraii, A et al.. Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2021;10 (17):e022222. doi: 10.1161/JAHA.121.022222. PubMed PMID:34459238 .
  7. Anker, SD, Butler, J, Filippatos, G, Ferreira, JP, Bocchi, E, Böhm, M et al.. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; :. doi: 10.1056/NEJMoa2107038. PubMed PMID:34449189 .
  8. Ha, ACT, Verma, S, Mazer, CD, Quan, A, Yanagawa, B, Latter, DA et al.. Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical Trial. JAMA Netw Open. 2021;4 (8):e2121867. doi: 10.1001/jamanetworkopen.2021.21867. PubMed PMID:34448866 PubMed Central PMC8397929.
  9. Bhatt, RD, Libby, P, Verma, S, Mason, RP, Bhatt, DL. The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization. Prog Cardiovasc Dis. 2021; :. doi: 10.1016/j.pcad.2021.08.003. PubMed PMID:34419485 .
  10. Syed, IM, Yanagawa, B, Jeyaganth, S, Verma, S, Cheema, AN. Injection Drug Use Endocarditis: An Inner-City Hospital Experience. CJC Open. 2021;3 (7):896-903. doi: 10.1016/j.cjco.2021.02.015. PubMed PMID:34401696 PubMed Central PMC8347875.
Search PubMed

Affiliations & Other Activities

  • Cardiac Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor of Surgery and Pharmacology & Toxicology, University of Toronto
  • Canada Research Chair in Cardiovascular Surgery